TRAW
HEALTHCARETraws Pharma Inc
$1.70+0.12 (+7.59%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TRAW Today?
No stock-specific AI insight has been generated for TRAW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.97$3.27
$1.70
Fundamentals
Market Cap$24M
P/E Ratio1.9
EPS$0.82
Dividend Yield—
Dividend / Share—
ROE-10.6%
Profit Margin3.3%
Debt / Equity—
Trading
Volume136K
Avg Volume (10D)—
Shares Outstanding15.2M
TRAW News
20 articles- Sector Update: Healthcare Stocks Lower Late AfternoonYahoo Finance·May 8, 2026
- Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsYahoo Finance·May 8, 2026
- Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Yahoo Finance·Apr 20, 2026
- Traws Pharma, Inc. Q4 2025 Earnings Call SummaryMoby·Apr 16, 2026
- Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...Yahoo Finance·Apr 16, 2026
- Traws Pharma Reports Full Year 2025 Results and Provides Business HighlightsYahoo Finance·Apr 15, 2026
- Traws Pharma Announces Up to $60 Million Private Placement FinancingYahoo Finance·Apr 15, 2026
- hVIVO, Connecting Excellence, ACG Metals, Kodal Minerals, Ariana Resources, Sunda EnergyYahoo Finance·Apr 14, 2026
- Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal InfluenzaYahoo Finance·Feb 19, 2026
- Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal InfluenzaYahoo Finance·Jan 26, 2026
- Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 PatientsYahoo Finance·Jan 13, 2026
- TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of DirectorsYahoo Finance·Dec 22, 2025
- Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 PatientsYahoo Finance·Dec 17, 2025
- Traws Pharma Reports Third Quarter 2025 Results and Business HighlightsYahoo Finance·Nov 13, 2025
- ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical TrialsYahoo Finance·Oct 30, 2025
- Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.Yahoo Finance·Oct 22, 2025
- Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025Yahoo Finance·Oct 14, 2025
- Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key ExecutivesYahoo Finance·Oct 6, 2025
- Annovis Appoints Mark Guerin as Chief Financial OfficerYahoo Finance·Sep 25, 2025
- Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025Yahoo Finance·Aug 18, 2025
All 20 articles loaded
Price Data
Open$1.61
Previous Close$1.58
Day High$1.75
Day Low$1.55
52 Week High$3.27
52 Week Low$0.97
52-Week Range
$0.97$3.27
$1.70
Fundamentals
Market Cap$24M
P/E Ratio1.9
EPS$0.82
Dividend Yield—
Dividend / Share—
ROE-10.6%
Profit Margin3.3%
Debt / Equity—
Trading
Volume136K
Avg Volume (10D)—
Shares Outstanding15.2M
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—